

INTEGRATING AI DECISION-SUPPORT SYSTEMS IN RENAL SURGERY: ENHANCING ACCURACY AND PERIOPERATIVE OUTCOMES

Roodrya B Patel¹, Vinay Badangi², Dr. Prem Chand Lamab³, Ajay Singh⁴, Dr. S.Arukumar⁵

¹Medical Student, Department of MD, AMA SCHOOL OF MEDICINE, MAKATI -1233, Orcid ID: 0009-0001-6953-3863, Email ID: roodhraypatel@gmail.com

²General Surgery Resident 3rd year, Department of General Surgery, University: Dr D Y Patil Medical College Hospital and Research Centre, Pune. Email ID: vinaybadangi77@gmail.com, ORCID ID: 0009-0009-4077-1356

³Mgumst Jaipur, MBBS, MD physiology, Email ID: drpremlamba@yahoo.co.in

⁴Assistant Professor, Department of Computer Science and Engineering, Inderprastha Engineering College, Ghaziabad. Email ID: ajaysinghgucs@gmail.com

⁵Professor, Department of General Medicine, Vinayaka Missions Medical College, Karaikal. (Vinayaka Missions Research Foundation), avsarun.kkl@gmail.com mikky main, ORCID ID: 0000-0002-0326-9473

ABSTRACT

Renal surgery has evolved toward minimally invasive and nephron-sparing approaches, requiring complex, data-intensive decision-making to balance oncologic control with functional preservation. Artificial intelligence-based decision-support systems (AI DSS) have emerged as promising tools to augment clinical judgment by integrating multimodal data across the perioperative continuum. However, their clinical role, evidence base, and implementation challenges in renal surgery remain incompletely defined. This review aims to critically evaluate the current and emerging applications of AI decision-support systems in renal surgery, with a focus on enhancing surgical accuracy and perioperative outcomes. A narrative review of recent literature was conducted, emphasising guideline-based management, AI methodologies, and clinical studies published between 2020 and 2025. Evidence was synthesised across preoperative, intraoperative, and postoperative phases of renal surgery, with attention to validation status, ethical considerations, and real-world implementation barriers. AI DSS demonstrate significant potential in preoperative risk stratification, tumour characterisation, and surgical planning; intraoperative guidance through computer vision, augmented reality, and robotic assistance; and postoperative complication prediction and outcome optimisation. Despite encouraging performance metrics, most AI models have been validated retrospectively, with limited prospective and multicentre evidence. Key challenges include data quality, model generalizability, explainability, regulatory oversight, and clinician acceptance. AI decision-support systems represent a powerful adjunct to contemporary renal surgery, offering opportunities to improve precision and perioperative outcomes. Realising their full clinical impact will require rigorous validation, ethical governance, and seamless integration into surgical workflows to ensure safe, equitable, and effective adoption.

KEYWORDS: Artificial intelligence; renal surgery; decision-support systems; perioperative outcomes

INTRODUCTION

The field of renal surgery has been radically reformed within the last few decades as the methods of open extirpation operation changed to minimally invasive, nephron-sparing, and robotised approaches. This development has been facilitated by a parallel development of imaging, surgical technology and a growing focus on renal preservation with oncologic efficacy. Evidence-supported recommendations currently determine the management of renal masses based on the personalisation of treatment choices, the trade-off between tumour features, comorbidities in the patient, and functional outcomes in the long-term [1,2].

Though characterised by these improvements, clinical decision-making in renal surgery is still complex in nature. The surgeons are required to combine heterogeneous information, such as anatomy imaging, tumour biology, baseline renal performance, and patient-specific risk factors that are usually time-constrained and have incomplete information. The clinical tools of the past, including nephrectomy scoring systems and guideline-based algorithms, offer a useful framework but are constrained by interobserver reliability and the inability to represent nonlinear interactions among variables in full. With the growing complexity of the surgical candidates, especially in older patients and patients with severe comorbidities, the necessity to involve more advanced decision-support mechanisms has become ever more noticeable.

Artificial intelligence (AI) has become a promising solution to these problems as it allows data-oriented, adaptive, and scalable clinical decision support. The AI decision-support system (AI DSS) uses machine learning and deep learning to process the large amount of multimodal data and produce predictive information that may be used to inform the surgical planning process and perioperative management. The initial uses of AI in urology have been shown to be promising in a diverse spectrum of applications, such as imaging interpretation, outcomes prediction, workflow optimisation, and robotic assistance [3]. These capabilities position AI DSS as a natural extension of precision medicine in renal surgery.

In renal cancer, care-based practises are getting more focused on personalised risk evaluation and specific surgery plans, which are guided by the guidelines. According to the latest amendments of the European Association of Urology guidelines, the preference for personalised treatment choice is especially significant when it comes to the choice of partial

versus radical nephrectomy, active surveillance, and minimally invasive treatment options [2,4]. AI DSS can be used to implement these recommendations by incorporating patient- and tumour-specific information into actionable predictions to facilitate shared decision-making and maximise perioperative outcomes.

Early clinical research indicates that models based on AI have the potential to improve risk stratification and functional outcome prediction in renal surgery. To illustrate, AI-based models have been trained to forecast the postoperative renal function after minimally invasive partial nephrectomy, and could provide person-specific prognostic information, as opposed to conventional clinical factors [5]. These models illustrate the possible prospect of AI DSS to facilitate nephron-sparing approaches and reduce the risk of long-term renal failure, which is a major factor in renal cancer treatment nowadays.

The introduction of AI DSS in regular renal surgery is still in its infancy. Technological feasibility has been developed at high speed, but the issue of clinical validity, generalisability, ethical governance, and real-world implementation of technology continues to arise. The differences in the quality of data, a lack of prospective validation, and the issue of transparency and accountability remain limiting factors to mass adoption [3]. In addition, the implementation of AI in the decision-making process of high-stakes surgery brings up pertinent questions of clinician trust, medicolegal accountability, and adherence to existing standards of care.

It is against this background that a thorough synthesis of the existing evidence is required to explain the place of AI DSS in renal surgery and where safe and successful clinical translation pathways can be found. The review of the literature is usually either more devoted to definite technical usage or definite stages of surgical treatment, but there is no overall, perioperative overview. To educate clinicians, researchers and policymakers, a systematic analysis of the potential use of AI DSS to improve accuracy and outcomes in preoperative planning, intraoperative guidance, and postoperative management is necessary.

The objective of this review is to critically examine the integration of artificial intelligence-based decision-support systems (AI DSS) in renal surgery, with a particular focus on their impact on surgical accuracy and perioperative outcomes. Specifically, this review aims to:

Describe the conceptual framework underpinning AI decision-support systems in surgical care

Evaluate current AI-driven applications across the preoperative, intraoperative, and postoperative phases of renal surgery

Assess the quality, strengths, and limitations of the existing clinical evidence supporting AI DSS

Discuss the ethical, regulatory, and implementation challenges associated with the clinical adoption of AI-based decision support

Contextualising AI DSS into the modern guideline-based renal cancer care and surgery, this review aims to present a moderate and clinically balanced opinion on the potential and the challenges of AI integration. Since the future of renal surgery is clearly moving towards more individualised care, AI DSS could become a key component in the informed decision-making process and enhance patient outcomes as long as their creation and implementation are informed by evidence and ethical accountability.

2. Conceptual Framework of AI Decision-Support Systems in Surgery

Artificial intelligence (AI) surgery decision-support systems (DSS) are computational devices that help clinicians to use complex and multimodal data to generate actionable clinical insights to guide clinical decision-making in the perioperative continuum. Unlike conventional rule-based clinical decision applications, AI DSS can take advantage of the data-driven learning algorithms that can detect nonlinearities, adapt to new data, and scale to different clinical settings [6].

2.1 Definition and Taxonomy of AI Decision-Support Systems

The AI DSS in surgical care can be divided into various basic categories depending on their purpose and autonomy. One of these systems is an assistive decision-support system that can offer recommendations but leave the ultimate decision to the surgeon, and the other type is more advanced and includes context-aware systems that can give support in real-time during the intraoperative process. Recent systems state that AI DSS shall complement human experience and not substitute it, which is consistent with the new standards of transparency, accountability, and clinical control [7].

Methodologically, there are also other methodological classifications of AI DSS, based on their learning paradigm, such as supervised, unsupervised, and reinforcement learning models, which apply to the various types of surgical tasks, including risk prediction, pattern recognition, and workflow optimisation [8].

2.2 Core AI Methodologies Used in Renal Surgery

Machine Learning and Deep Learning

Most modern AI DSS are based on machine learning (ML), which uses statistical and algorithmic methods to identify patterns in structured clinical data that is structured. Deep learning (DL), which is a subdivision of ML, involves the use of multilayer neural networks to process high-dimensional data, especially medical imaging and video data. DL has shown better results in surgical tasks that involve the use of complex features, e.g., anatomical part segmentation and surgical stage identification [9].

Computer Vision

Computer vision allows visual data, such as preoperative images and intraoperative video feeds, to be interpreted automatically. Computer vision models are used in renal surgery to identify landmarks of anatomy, localise tumours, and guide the workflow during robotic surgery. The applications form the basis of intraoperative DSS in real-time by offering situational awareness and the context of the procedure [8,9].

Natural Language Processing

Natural language processing (NLP) is useful in extracting clinically relevant data from unstructured text, including operative notes, pathology reports, and radiology narratives. Although not as mature as imaging-based AI in the field of

renal surgery, NLP-enhanced DSS are promising in providing longitudinal outcome prediction and postoperative follow-up in the form of narrative clinical data by entering it into predictive models [8].

Data Sources Powering AI Decision-Support Systems

The quality and variety of data inputs inherently determine the effectiveness of AI DSS. Computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound are the leading sources of preoperative planning and intraoperative guidance imaging modalities. These are becoming ever more supplemented by systematic electronic health record (EHR) information, such as demographics, comorbidities, laboratory values and perioperative variables. Besides, intraoperative video feeds and sensor-based information of robotic platforms allow real-time viewing of the surgical workflow and performance [9].

2.3 Integration Models: Human-AI Collaborative Decision-Making

One of the main concepts of AI DSS application to surgery is human-AI collaboration, whereby insights that are generated by AI are incorporated into the clinical process without compromising surgeon autonomy. Regulatory and reporting frameworks emphasise explainability, validation, and constant performance monitoring to provide safe and effective integration into practise [6,7]. Other reporting standards, including TRIPOD+AI and CONSORT-AI, also support the importance of making the methods transparent and the results interpretable by clinicians, especially since AI DSS are not experimental tools but are becoming a regular part of surgery [6,10]. Artificial intelligence decision-support systems operate across the perioperative continuum, integrating diverse data streams to support clinical decision-making (Table 1).

Table 1. Overview of Artificial Intelligence Decision-Support Systems Across the Perioperative Continuum in Renal Surgery

Perioperative Phase	AI Methodology	Data Inputs	Clinical Task	Decision-Support Output
Preoperative	ML, DL, Radiomics	CT, MRI, EHR	Risk stratification, tumour characterisation	Surgical feasibility, risk scores
Intraoperative	Computer vision, DL	Video, AR overlays	Anatomical recognition, workflow analysis	Real-time guidance, alerts
Postoperative	ML, XAI	Labs, vitals, imaging	Complication prediction	Early warning, follow-up plans

3. Preoperative Decision Support in Renal Surgery

The preoperative decision-making in renal surgery is a complex process that needs the incorporation of factors related to anatomy, functional, oncological, and patient-specific data. AI DSS are now powerful tools that can help improve the accuracy, decrease inter-observer variation, and assist in the customisation of surgical planning prior to intervention.

3.1 Patient Selection and Risk Stratification

Risk stratification and proper patient selection are the most important elements of perioperative renal surgery optimisation. The use of AI-based models allows predicting the complexity and feasibility of surgery through the analysis of multidimensional data, including imaging-based anatomical characteristics and patient-specific clinical variables. Such models would help surgeons to predict technical difficulties and adjust the operative plans to them. Figure 1 provides an overview of the AI-driven preoperative decision-support pipeline of patient selection and risk stratification in renal surgery.




Figure 1. Artificial intelligence-driven preoperative decision-support pipeline in renal surgery.

Radiomics and machine learning strategies have proven useful in predicting treatment and survival in renal cell carcinoma, thus adding to the preoperative risk prediction of the disease in addition to the conventional clinicopathological variables [11]. Through the combination of imaging biomarker and patient comorbidity, AI DSS can produce comorbidity-adjusted outcomes of adverse events, such as postoperative acute kidney injury and postoperative complications, to inform better patient counselling and shared decision-making.

Moreover, AI-supported, systematic strategies allow customising surgical planning due to the quantification of risk-benefit trade-offs of specific patients. These instruments can be used to promote open communication between the surgeons and patients, especially when it comes to the balancing of oncologic control and functional preservation in borderline cases.

3.2 Tumour Characterisation and Surgical Planning

Tumour characterisation is one of the most developed applications of AI in preoperative planning of renal surgery. Models that are developed using deep learning have demonstrated high accuracy in automated renal tumour detection and segmentation on computed tomography, enabling the accurate delineation of parenchyma and tumour boundaries in the kidneys [12,13]. Similar approaches have been extended to broader renal pathology, including stone and tumour segmentation, demonstrating the scalability of AI-driven imaging analysis [14].

In addition to segmentation, AI-aided nephrectomy scoring systems provide objective tumour complexity measurements. More simplified and automated nephrectomy techniques, like the SPARE scoring system, can minimise interobserver variability and increase reproducibility over conventional scoring systems to make surgical decisions more consistent [15]. Machine learning models based on radiomics additionally allow the prediction of malignancy of tumours, histological subtype, and aggressiveness. Research has demonstrated that intratumoral and subregional radiomic data can be effectively used to predict histological grade in clear cell renal cell carcinoma, and are more effective than conventional imaging evaluation [16,17]. Multi-parameter MRI-based machine learning models have been shown to perform better in cystic renal masses than the Bosniak 2019 classification, helping to preoperatively differentiate between benign and malignant masses of the kidney [18,19].

Together, these developments offer highly essential decision support in the judgment of the suitability of partial versus radical nephrectomy, especially in anatomically challenging or oncologically uncertain situations. Key preoperative AI applications supporting tumour characterisation and surgical planning are summarised in Table 2.

Table 2. Preoperative AI Applications for Tumour Characterisation and Surgical Planning in Renal Surgery

AI Application	Input Modality	Model Type	Clinical Objective	Potential Impact
Tumour segmentation	CT/MRI	Deep learning	Accurate tumour delineation	Improved surgical planning
Radiomics grading	CT/MRI	ML	Predict histologic grade	Risk-adapted surgery
Cystic mass classification	MRI	ML/DL	Benign vs malignant	Partial vs radical decision
Nephrectomy automation	Imaging	ML	Complexity scoring	Reduced variability

3.3 Functional Preservation and Nephron-Sparing Strategies

Renal preservation is one of the main aims of modern renal surgery. AI DSS can be used in nephron-sparing approaches because they allow predictive modelling of postoperative renal functionality using preoperative imaging and clinical information. The use of radiomics-based models has shown itself capable of estimating the response to treatment and long-term functional outcome to support personalised surgical plans that are intended to result in the maximum preservation of nephrons [11].

Advanced preoperative planning, such as three-dimensional virtual and metaverse-based surgical planning systems, enables surgeons to simulate complex resections, optimise ischemia plans and selective arterial clamping plans with more accuracy [20]. These systems can be used to optimise the time of ischemia and to enable custom nephron-sparing strategies in problematic cases through the combination of AI-informed anatomical knowledge and surgeon experience.

4. Intraoperative AI-Driven Decision Support

The intraoperative stage is a critical period during which AI-based decision-support systems (AI DSS) can be used to improve the precision of surgical interventions, situational awareness, and patient safety. Through the use of real-time data feeds of imaging, video, and robot systems, AI DSS can offer active and context-sensitive support that complements the performance of surgeons during complicated renal surgeries.

4.1 Real-Time Surgical Guidance

AI systems based on computer vision have been shown to have a high potential in identifying anatomical landmarks and providing instructions for surgical activities during minimally invasive renal surgery. Through the analysis of intraoperative video feeds, these systems may detect critical structures, including renal vasculature, tumour boundaries, and dissection planes, thus eliminating the need to use subjective visual interpretation.

Image fusion technologies and augmented reality (AR) technologies can also expand on those features by superimposing preoperative imaging data on the intraoperative surgical field. It has been demonstrated that AI-based systems of AR navigation can be used to improve spatial orientation and surgical accuracy during minimally invasive partial nephrectomy to allow accurate tumour localisation and identification of the margin without damaging healthy parenchymal tissue [21]. These systems help in real-time decision-making through constant synchronisation of virtual anatomy models with live surgical images.

4.2 Robotic and Image-Guided Renal Surgery

The introduction of AI into robotic surgical systems has revolutionised image-guided renal surgery because it has introduced dynamic motion control, workflow optimisation, and procedural support. Instrument trajectories and surgeon movements can be evaluated by AI algorithms installed on robots to aid in tremor filtration and ergonomics optimisation, which enhances the technical quality of action during the delicate parts of the surgery [22].

The most important part of robotic-assisted renal surgery is the use of context-aware AI systems that are able to identify surgical stages. It was established that computer vision models can be trained to recognise surgical phases with similar or better performance to human observers and therefore can be used in real-time to guide surgical procedures [23]. These capabilities enable adaptive assistance, such as anticipating upcoming steps or adjusting system parameters based on the

current phase of surgery. The integration of computer vision, robotic data, and context-aware decision support within an AI-augmented intraoperative environment is depicted in Figure 2.




Figure 2. Intraoperative AI-augmented surgical environment in renal surgery.

Narrative reviews of intraoperative AI applications in urologic surgery also stress the fact that there is an increased overlap between robotics and AI and that intelligent systems can be used to improve consistency, efficiency, and safety in complex oncologic surgeries [24].

4.3 Intraoperative Risk Prediction and Error Prevention

In addition to guidance and automation, AI DSS are being progressively designed to forecast the intraoperative risks and to avoid in-time mistakes. These systems have surgical phase recognition, which is a baseline element, as it allows the identification of the high-risk sections of the procedure in terms of bleeding, ischemic injury, or technical complications [25].

Sophisticated surgical phase recognition and anticipation models have the potential to decrease cognitive load by issuing prompt warnings and decision cues in order to assist the surgeon in their attention at the most critical points [26]. The AI DSS can also serve as a safety net by constantly tracking the patterns and deviations in the workflow, warning surgeons of possible dangers and enabling them to mitigate them proactively.

Taken together, these intraoperative artificial intelligence applications represent a transition to intelligent, adaptive operating rooms where human knowledge can be enhanced by real-time computational understanding. Current intraoperative applications of AI-driven decision support in renal surgery are outlined in Table 3.

Table 3. Intraoperative AI-Driven Decision Support Applications in Renal Surgery

Intraoperative Task	AI Technique	Data Source	Clinical Benefit	Maturity Level
Landmark recognition	Computer vision	Video	Reduced anatomical errors	Experimental-Early clinical
Surgical phase recognition	DL	Video	Workflow optimization	Experimental
AR navigation	AI + AR	CT + video	Improved spatial orientation	Early clinical
Risk alerts	ML	Sensor/video	Error prevention	Experimental

5. Postoperative Decision Support and Outcome Optimisation

The management of postoperative renal surgery is a decisive factor of the short- and long-term outcomes. Decision-support systems (AI DSS) based on artificial intelligence are being increasingly used to support postoperative care to facilitate

early detection of complications, recovery pathways, and tailored follow-up plans depending on the risk profile of a particular patient.

5.1 Complication Prediction and Early Detection

Early detection of postoperative complications has been a key objective in kidney surgery, especially in adverse renal events like acute kidney injury (AKI). AI predictive models have shown high efficacy in predicting either postoperative renal function deterioration after radical and partial nephrectomy through a combination of imaging-based features and perioperative clinical variables [5,27].

Explainable machine learning models have also been shown to facilitate the prediction of AKI following robot-assisted partial nephrectomy and provide interpretable risk estimates that can be used in real-time to guide clinical decision-making. These models have been demonstrated to be superior to traditional risk stratification methods in multicentre validation studies in which earlier intervention and more targeted monitoring of high-risk patients can be performed [28]. In addition to renal-specific complications, AI DSS can predict a wider range of negative postoperative outcomes, such as bleeding, infection, and hospital readmission. Based on the constant streams of multimodal data, including laboratory trends, vital signs, and postoperative imaging, AI-based clinical decision-support tools can be used to monitor complications before they arise and escalate care in a timely manner [29].

5.2 Enhanced Recovery and Personalised Follow-Up

AI DSS also contribute to the maximum postoperative recovery and long-term outcome monitoring. Customised predictive algorithms have been created to predict long-term renal functional patterns following nephrectomy so that clinicians can customise post-surgery care plans and counselling according to personal risk profiles [30,31].

Such predictive insights can be used to develop AI-assisted postoperative care plans, such as enhanced recovery plans that modify the intensity of monitoring, medication plans, and follow-up plans based on patient-specific risk. AI DSS could help optimise resources by forecasting the length of stay and recovery curves with high precision and avoiding substandard treatment of patients [29].

Moreover, AI-based surveillance plans provide the potential of personalised oncologic follow-up due to the capacity to detect patients who are at risk of disease recurrence or functional deterioration. With the combination of longitudinal clinical and imaging data, AI DSS assist in adaptive follow-up schedules, which ensure that unnecessary interventions are limited at the expense of early detection [27].

6. Clinical Validation and Evidence Landscape

Clinical validation of artificial intelligence-based decision-support systems (AI DSS) in renal surgery is a developing field, and most of the evidence is obtained through retrospective and observational studies. Although technological advancements have enhanced the development of models, it is important that models are properly tested against laid-down clinical standards to ascertain safety, reliability, and clinical usefulness before extensive use.

6.1 Overview of Existing Clinical Studies and Trials

The existing data to support the use of AI DSS in kidney surgery is primarily informed by the research carried out to assess the results of the complex surgeries, specifically robot-assisted partial nephrectomy (RAPN). There is support in systematic reviews and meta-analyses to support the positive perioperative, functional, and oncologic results of RAPN in complicated clinical settings, such as large tumours, solitary kidneys, and anatomically challenging lesions [32,33]. These outcome data provide a critical reference framework against which AI-assisted decision-support tools can be evaluated. Comparative studies that evaluate the robotic versus open partial nephrectomy also provide additional context that shows the possible value of AI DSS because it indicates performance standards related to modern surgical standards. The propensity-matched studies have demonstrated that RAPN is capable of producing similar oncologic safety with better perioperative outcomes, which support the necessity of AI models to reach or surpass these performance benchmarks [34].

6.2 Retrospective Versus Prospective Validation Studies

The majority of AI DSS used in renal surgery have been retrospectively validated on institutional datasets, which limits their generalizability because of selection bias and institutional practise patterns. Prospective validation studies are, in contrast, limited, which highlights the gap in evidence base as a critical gap. The current clinical guidelines state that prospective, multicentre validation is essential to illustrate the reproducibility of the results, as well as the clinical impact of the results in a variety of patient groups and health care environments [2].

6.3 Performance Metrics and Benchmarking Standards

Discrimination, calibration, and clinical utility are usually used as metrics in the performance evaluation of AI DSS. Nevertheless, there are no standard benchmarking frameworks, which makes it difficult to compare studies across. Current surgical outcome benchmarks based on high-quality RAPN studies can be useful comparators in determining whether AI-driven recommendations can be converted into measurably improved perioperative safety, functional preservation, and oncologic outcomes [32,33].

6.4 Comparison with Traditional Clinical Risk Models

Preoperative decision-making in renal surgery is based on traditional clinical risk models and nephrectomy scoring systems. The AI DSS should then be able to show incremental value over these well-established tools to warrant its integration into practice. The comparison with guideline-based standards of care demonstrates the necessity of clear reporting and clinically meaningful outcomes, which is accentuated by the current RCC management guidelines [2].

6.5 Gaps in High-Quality, Multicentre Evidence

Although there are encouraging preliminary findings, there are still a lot of missing links in the clinical validation of AI DSS in renal surgery. A significant deficit of randomised studies, prospective multicentre research, and real-world implementation research is apparent. It will be crucial to correct these gaps in order to transform AI DSS into validated clinical adjuncts that can change the recommendations of guidelines and the standard practise [2].

7. Ethical, Legal, and Regulatory Considerations

Implementation of artificial intelligence-based decision-support systems (AI DSS) in renal surgery presents critical ethical, legal, and regulatory issues that need to be considered to achieve safe, fair, and reliable clinical practise. As AI systems continue to have an impact on high-stakes surgical decisions, it is necessary to have institutions of strong governance to ensure that there is clinician oversight and patient trust.

7.1 Transparency, Explainability, and Trust in AI DSS

The clinical acceptance of AI DSS depends on the presence of transparency and explainability. When AI-generated recommendations are used to make perioperative decisions, surgeons should be capable of comprehending and critically assessing such recommendations. Explainable artificial intelligence (XAI) methods attempt to make model outputs explainable through emphasising important input features and decision paths, hence facilitating clinician trust and responsibility [35].

The transparency of reporting and methodologies is also enhanced by systematic guidelines like TRIPOD+AI, which include the focus on the articulate documentation of the model development, validation, and clinical utility. Compliance with such standards increases the reproducibility and reduces the risk of unsuitable clinical use [6].

7.2 Bias, Fairness, and Data Representativeness

Unrepresentative training datasets can result in bias in AI DSS and cause systematic differences in model performance across populations of patients. Such biases can be disproportionately used in renal surgery when the patient has atypical anatomy, comorbid conditions, or underrepresented demographic features. The international consensus frameworks emphasise that the variety of datasets and their constant monitoring of model performance needs to be encouraged to support fairness and equity in AI-assisted care [36]. Ensuring data representativeness and addressing algorithmic bias are therefore essential ethical obligations, particularly as AI DSS are scaled across institutions and healthcare systems with heterogeneous patient populations.

7.3 Medicolegal Responsibility and Liability in AI-Assisted Decisions

The implementation of AI DSS in surgical decision-making raises difficult issues of medicolegal responsibility and liability. Although AI systems have the potential of affecting clinical judgments, the overall patient care is still the responsibility of the clinician. The roles of human decision-makers and AI tools should be clearly outlined to eliminate the possibility of ambiguity when it comes to accountability, particularly when bad things happen [7]. Legal frameworks must evolve in parallel with technological innovation to clarify standards of care and liability in AI-assisted surgery, balancing innovation with patient safety.

7.4 Regulatory Pathways and Oversight

Regulatory bodies have started to lay the groundwork for evaluating and granting the approval of AI-based medical software. The U.S. Food and Drug Administration framework of software as a medical device (SaMD) offers premarket assessment, postmarket monitoring, and management of adaptive algorithms using pre-established change management plans [37].

Globally, the harmonisation of regulatory norms and principles of trustworthiness, including those provided in the FUTURE-AI consensus guideline, focuses on the value of safety, transparency, and clinical efficacy in AI DSS implementation [36]. Such regulatory initiatives are also essential to the ability of AI innovations in the field of renal surgery to translate into quantifiable patient impact without undermining ethical and legal principles.

8. Implementation Challenges and Barriers to Adoption

Although the artificial intelligence-driven decision-support systems (AI DSS) have accumulated substantial evidence on the efficacy of such systems in renal surgery, their application in clinical practice is limited by various implementation issues. These barriers should be countered to make sure that technological progress brings about sustainable and fair changes in patient care.

8.1 Data Quality, Interoperability, and Standardisation Issues

The interoperable and high-quality data are the cornerstones of the stable performance of AI DSS. The data acquisition protocols, quality of imaging, and electronic health record (EHR) structures of different institutions may exhibit significant variability, which may impact the generalizability of the model and its strength. The lack of interoperability between different data standards and inconsistent data standards prevents the smooth integration of AI tools into the current healthcare infrastructures, making it more likely that performance will decrease as models are implemented out of the contexts in which they were developed [38,39]. Standardising data formats, imaging protocols and outcomes definitions are thus important to facilitate scalable and reproducible implementation of AI DSS in a wide variety of clinical settings.

8.2 Integration into Clinical Workflows and Surgical Training

To ensure the successful implementation of AI DSS into clinical practise, it is crucial to align it with the current surgical procedures and to cause minimal interference to the efficiency of the working process. Ill-integrated systems can pose a danger of augmenting cognitive load instead of reducing it. Implementation studies also focus on the significance of co-designing AI tools with end users in order to achieve usability and relevance to context [39].

Simultaneously, the inclusion of AI literacy in the curricula of surgical training is becoming more widely accepted as a requirement for successful adoption. To use AI-assisted decision-making safely, surgeons should be prepared to read AI outputs, identify the limitations, and provide the necessary clinical supervision [38].

8.3 Surgeon Acceptance and Human Factors Engineering

Surgeon acceptance is one of the determinants of AI DSS uptake. Perceived reliability, transparency, and compatibility with clinical judgement affect the trust in AI systems. Systematic reviews have shown mixed rates of credibility among

health care practitioners, bringing up issues that are associated with explainability, accountability and loss of autonomy [40].

Human factors engineering is key in dealing with these issues by streamlining the information presentation, flow of interaction and interface design. AI DSS, which boosts situational awareness without overwhelming users, will be better accepted and maintained in high-stakes surgical settings [40,41].

8.4 Cost-Effectiveness and Resource Considerations

Economic factors are also a major obstacle to the extensive use of AI DSS. The cost of initial development, validation, integration and maintenance can be high, especially for resource-starved healthcare systems. The surveys of health system leaders indicate that they require a clear demonstration of the cost-effectiveness and value-based results to support the investment in AI technologies [41].

It will be necessary to demonstrate the tangible benefits in the form of a decreased rate of complications, optimisation of resource use, and enhanced efficiency to support sustainable implementation and inform policy and reimbursement choices [38]. The major clinical, technical, ethical, and implementation-related barriers to the adoption of AI decision-support systems in renal surgery are summarised in Table 4.

Table 4. Key Challenges, Evidence Gaps, and Implementation Barriers for Artificial Intelligence Decision-Support Systems in Renal Surgery

Domain	Current Challenges	Clinical Impact	Mitigation Strategies
Clinical validation	Predominantly retrospective studies	Limited generalizability	Prospective multicentre trials
Data quality	Heterogeneous imaging and EHR data	Model performance drift	Standardisation and curation
Ethics and trust	Limited explainability	Reduced clinician acceptance	Explainable AI frameworks
Workflow integration	Poor system interoperability	Increased cognitive burden	Human-centered design
Cost and resources	High development and maintenance costs	Restricted scalability	Health economic evaluation

9. Future Directions and Emerging Innovations

The high rate of artificial intelligence-based decision-support systems (AI DSS) development in renal surgery is an indicator of the paradigm shift in the more specific, adaptive, and patient-centred approach to surgery. New technologies will take existing AI systems to the next level of task-oriented support to whole-surgical intelligence.

9.1 Multimodal and Foundation Models in Renal Surgery

The next-generation AI DSS will build on the notion of multimodal learning, where heterogeneous data streams (imaging, electronic health records, genomics, intraoperative video, sensor data) are combined into single predictive models. Pretrained on a variety of data and further trained on particular surgical tasks, large-scale foundation models provide the opportunity to enhance generalizability, decrease the necessity of data, and provide transfer learning across institutions and procedures.

In renal surgery, these models may provide concomitant support to tumour characterisation, risk stratification, intraoperative guidance, and postoperative outcome prediction, which will decrease the discontinuity of the perioperative continuum and improve decision coherence.

9.2 Federated Learning and Privacy-Preserving AI

Regulatory limitations and data privacy are the primary obstacles to the creation of large-scale AI in healthcare. Federated learning and other privacy-preserving methods allow institutions to jointly train a model without having to share their data centrally. These strategies will enable building a strong, externalizable AI DSS as the local data will be left on-site, and the model parameters will be shared, without breaking the rules of data protection.

Federated learning can help to implement multicentre validation in renal surgery, minimise institutional bias, and faster translate AI DSS into different clinical settings.

9.3 Digital Twins and Predictive Simulation of Surgical Outcomes

Digital twins Virtual models of specific patients, which dynamically simulate anatomy, physiology, and disease development, are a radical innovation in the field of surgical planning and decision support. Digital twins in renal surgery may allow predictive modelling of various surgical plans, predicting the functional and oncologic results in the different conditions of ischemia, resection level or clamping methods.

Digital twins have the potential to greatly increase precision, uncertainty reduction, and shared decision-making with patients by enabling surgeons to preoperatively test and optimise surgical procedures.

9.4 AI-Driven Autonomous and Semi-Autonomous Surgical Systems

Although full autonomy surgery is still a far-off dream, semi-autonomous AI systems that are capable of helping with individual subtasks in surgery are becoming a reality. These are automated camera control, suturing assistance, perfect positioning of instruments, and safety control during critical operation periods. Such systems can add to the performance of the surgeon in technically challenging moves in renal surgery, keeping human control and oversight intact.

The constant movement toward the transitional stage of semi-autonomous systems into assistive systems highlights the need to keep ethical protection, strict validation, and the division of human and AI functions.

9.5 Roadmap Toward Precision Renal Surgery

Taken together, these developments are all indicative of a future of precision renal surgery, with individualised risk prediction, personalised operative plans, real-time adaptive guidance, and individualised postoperative treatment. This vision will not be possible to achieve without interdisciplinary collaboration of surgeons, data scientists, engineers, regulators, and ethicists and long-term investment in clinical validation and implementation science.

Finally, technical performance will be only one of the conditions that will allow the successful integration of emerging AI technologies into renal surgery, coupled with trust, transparency, and provable patient benefit. With innovation and clinical need matching with ethical responsibility, AI DSS can transform surgical decision-making and outcomes in renal surgery.

10. CONCLUSIONS

DSS based on artificial intelligence is quickly changing the face of renal surgery by adding precision, consistency, and personalisation throughout the perioperative continuum. Application in preoperative risk stratification and surgical planning, intraoperative real-time guidance, and postoperative outcomes optimisation have shown significant possibilities of AI DSS to support clinical decision-making processes and enhance perioperative outcomes without taking away the autonomy of surgeons. The existing evidence has shown significant progress in the imaging characterisation of tumours, prediction of functional outcome, workflow recognition, and complication monitoring. Nevertheless, the clinical effect of these technologies is disproportionate, as the majority of the systems are confirmed in retrospective or single-centre studies. To close this gap, the stringent prospective, multicentre validation studies, standardised performance benchmarking and transparent reporting in line with the new methodological and regulatory frameworks will be needed. The ethical, legal and implementation issues related to the integration of AI into surgical care are equally important. Data quality, bias, explainability, clinician trust, and cost-effectiveness issues should be resolved to achieve safe, equitable, and sustainable adoption. Regulatory systems are shifting towards adaptive AI systems, yet close co-operation between clinicians, developers, regulators and health systems will be required in successful translation. In the future, multimodal learning, federated and privacy-sensitive AI, digital twins, and semi-autonomous surgical systems are pointers to the real shift towards precision-driven renal surgery. Considerably applied, AI DSS could not only assist with the decision-making process in surgery but also remake the standards of care through the provision of data-driven and individualised treatment plans. To sum up, AI decision-support systems constitute a potent supplement to renal surgery, which can be used to increase accuracy and perioperative outcomes. To achieve their potential, further investment in clinical validation, ethical governance, and implementation science will be necessary to make sure that innovation can be translated into quantifiable and significant patient outcomes.

REFERENCES

1. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. *Journal of Urology* 2021;206:199–208.
2. EAU Guidelines on RCC - INTRODUCTION - Uroweb n.d. <https://uroweb.org/guidelines/renal-cell-carcinoma> (accessed December 30, 2025).
3. Abid R, Hussein AA, Guru KA. Artificial intelligence in urology: current status and future perspectives. *Urologic Clinics* 2024;51:117–30.
4. Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology guidelines on renal cell carcinoma: the 2025 update. *European Urology* 2025.
5. Amparore D, Piana A, Simeri A, Pezzi V, Dio MD, Fiori C, et al. From planning to prognosis: predicting renal function after minimally-invasive partial nephrectomy with artificial intelligence. *Minerva Urology and Nephrology* 2025;77:401–7.
6. Collins GS, Moons KG, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+ AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. *Bmj* 2024;385.
7. Health C for D and R. Artificial Intelligence in Software as a Medical Device. FDA 2025.
8. Bellos T, Manolitsis I, Katsimperis S, Juliebo-Jones P, Feretzakis G, Mitsogiannis I, et al. Artificial intelligence in urologic robotic oncologic surgery: a narrative review. *Cancers* 2024;16:1775.
9. Liu Z, Chen K, Wang S, Xiao Y, Zhang G. Deep learning in surgical process modeling: A systematic review of workflow recognition. *Journal of Biomedical Informatics* 2025;104779.
10. Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK, Ashrafian H, et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. *The Lancet Digital Health* 2020;2:e537–48.
11. Khene Z-E, Tachibana I, Bertail T, Fleury R, Bhanvadia R, Kapur P, et al. Clinical application of radiomics for the prediction of treatment outcome and survival in patients with renal cell carcinoma: a systematic review. *World J Urol* 2024;42:541.
12. Karunanayake N, Lu L, Yang H, Geng P, Akin O, Furberg H, et al. Dual-Stage AI Model for Enhanced CT Imaging: Precision Segmentation of Kidney and Tumours. *Tomography* 2025;11:3.
13. Kan H-C, Fan G-M, Wei M-H, Lin P-H, Shao I-H, Yu K-J, et al. Automated kidney tumour segmentation in CT images using deep learning: A multi-stage approach. *Academic Radiology* 2025.
14. Ye F, Liu C, Wang J, Sun Q, Asklany S. Kidney stone and tumour segmentation by analyzing medical images using deep learning technique. *Engineering Applications of Artificial Intelligence* 2025;160:111878.
15. Weprin S, Falagario U, Veccia A, Nandan N, Emerson D, Ovanez C, et al. Simplified PADUA renal (SPARE) nephrectomy scoring system: external validation, interobserver variability, and comparison with RENAL and PADUA in a single-center robotic partial nephrectomy series. *European Urology Focus* 2021;7:591–7.

16. Alhussaini AJ, Steele JD, Jawli A, Nabi G. Radiomics machine learning analysis of clear cell renal cell carcinoma for tumour grade prediction based on intra-tumoural sub-region heterogeneity. *Cancers* 2024;16:1454.
17. Lv X, Dai X-M, Zhou D-Q, Yu N, Hong Y-Q, Liu Q. Subregion-based radiomics analysis for predicting the histological grade of clear cell renal cell carcinoma. *Frontiers in Oncology* 2025;15:1554830.
18. Kang H, Xie W, Wang H, Guo H, Jiang J, Liu Z, et al. Multiparametric MRI-Based machine learning models for the characterization of cystic renal masses compared to the Bosniak classification, version 2019: A multicentre study. *Academic Radiology* 2024;31:3223–34.
19. He Q-H, Tan H, Liao F-T, Zheng Y-N, Lv F-J, Jiang Q, et al. Stratification of malignant renal neoplasms from cystic renal lesions using deep learning and radiomics features based on a stacking ensemble CT machine learning algorithm. *Frontiers in Oncology* 2022;12:1028577.
20. Checcucci E, Amparore D, Volpi G, De Cillis S, Piramide F, Verri P, et al. Metaverse surgical planning with three-dimensional virtual models for minimally invasive partial nephrectomy. *European Urology* 2024;85:320–5.
21. Shi X, Yang B, Guo F, Zhi C, Xiao G, Zhao L, et al. Artificial intelligence based augmented reality navigation in minimally invasive partial nephrectomy. *Urology* 2025;199:20–6.
22. Goldenberg MG, Rodier S, Cacciamani G. Robotic Surgery and Artificial Intelligence: A Synergistic Nexus. *AUANews* 2024;29.
23. Mezzina M, De Backer P, Vercauteren T, Blaschko M, Mottrie A, Tuytelaars T. Surgeons versus computer vision: a comparative analysis on surgical phase recognition capabilities. *Int J CARS* 2025;20:1283–91.
24. Guduguntla A, Al-Khanaty A, Davey CE, Patel O, Ta A, Ischia J. A Review of the Intraoperative Use of Artificial Intelligence in Urologic Surgery. *Société Internationale d'Urologie Journal* 2025;6:5.
25. De Backer P, Peraire Lores M, Demuynck M, Piramide F, Simoens J, Oosterlinck T, et al. Surgical phase duration in robot-assisted partial nephrectomy: a surgical data science exploration for clinical relevance. *Diagnostics* 2023;13:3386.
26. Boels M, Liu Y, Dasgupta P, Granados A, Ourselin S. SuPRA: Surgical Phase Recognition and Anticipation for Intra-Operative Planning 2024.
27. Abdallah N, Rathi N, Heller N, Wood A, Campbell R, Benidir T, et al. A Fully Automated Artificial Intelligence-Based Approach to Predict Renal Function After Radical or Partial Nephrectomy. *Urology* 2025.
28. Li J, Xu L, Yu Y, Li X, Liu Y, Liu W, et al. Development and validation of an explainable machine learning model for predicting acute kidney injury after robot-assisted partial nephrectomy: a retrospective multicentre study. *BMC Nephrol* 2025.
29. Oei SP, Bakkes T, Mischi M, Bouwman RA, van Sloun RJG, Turco S. Artificial intelligence in clinical decision support and the prediction of adverse events. *Frontiers in Digital Health* 2025;7:1403047.
30. Xu L, Li C, Gao S, Zhao L, Guan C, Shen X, et al. Personalized prediction of long-term renal function prognosis following nephrectomy using interpretable machine learning algorithms: case-control study. *JMIR Medical Informatics* 2024;12:e52837.
31. Javid M, Eldefrawy M, Sridhar SR, Roy M, Rubens M, Manoharan M. Role of artificial intelligence in predicting the renal function after nephrectomy in renal cell carcinoma: a systematic review and meta-analysis. *Int Urol Nephrol* 2025;57:3097–106.
32. Pandolfo SD, Cerrato C, Wu Z, Franco A, Del Giudice F, Sciarra A, et al. A systematic review of robot-assisted partial nephrectomy outcomes for advanced indications: Large tumours (cT2–T3), solitary kidney, completely endophytic, hilar, recurrent, and multiple renal tumours. *Asian Journal of Urology* 2023;10:390–406.
33. Huang L, Wang J-Q. A meta-analysis of perioperative, oncological, and functional outcomes of robot-assisted partial nephrectomy for completely endophytic and hilar lesions. *Int Urol Nephrol* 2025;57:2359–70.
34. Gavi F, Fettucciari D, Rossi F, Panio E, Assumma S, Sanesi D, et al. Robot-assisted vs open partial nephrectomy: a propensity-matched analysis of perioperative outcomes and midterm oncologic safety. *Int Urol Nephrol* 2025.
35. Sadeghi Z, Alizadehsani R, Cifci MA, Kausar S, Rehman R, Mahanta P, et al. A review of Explainable Artificial Intelligence in healthcare. *Computers and Electrical Engineering* 2024;118:109370.
36. Lekadir K, Frangi AF, Porras AR, Glocker B, Cintas C, Langlotz CP, et al. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. *Bmj* 2025;388.
37. Health C for D and R. Software as a Medical Device (SaMD). FDA 2025. <https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd> (accessed December 30, 2025).
38. Huang X, Gu L, Sun J, Eils R. Bridging the gaps: Overcoming challenges of implementing AI in healthcare. *Med* 2025;6.
39. Nair M, Svedberg P, Larsson I, Nygren JM. A comprehensive overview of barriers and strategies for AI implementation in healthcare: Mixed-method design. *PLoS One* 2024;19:e0305949.
40. Tun HM, Rahman HA, Naing L, Malik OA. Trust in artificial intelligence-based clinical decision support systems among health care workers: systematic review. *Journal of Medical Internet Research* 2025;27:e69678.
41. Poon EG, Lemak CH, Rojas JC, Gupta J, Classen D. Adoption of artificial intelligence in healthcare: survey of health system priorities, successes, and challenges. *Journal of the American Medical Informatics Association* 2025;32:1093–100.